Welcome to our dedicated page for IGC Pharma SEC filings (Ticker: IGC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IGC Pharma, Inc. (NYSE American: IGC) SEC filings page on Stock Titan aggregates the company’s official disclosures to the U.S. Securities and Exchange Commission, providing a structured view of its regulatory and corporate history. As a Maryland-incorporated, clinical-stage biotechnology company focused on Alzheimer's disease, pharmaceutical cannabinoids, and AI-driven research, IGC Pharma uses SEC filings to report material events, capital transactions, governance actions, and financial reporting changes.
Investors reviewing IGC Pharma’s filings will find multiple Form 8-K current reports detailing key developments. Recent 8-Ks describe a registered direct offering under an effective Form S-3 shelf registration statement, including a Subscription Agreement for the sale of common stock and the intended use of proceeds for working capital and clinical development programs. Other 8-Ks outline the completion of a Sale of Assets and Manufacturing Agreement through the company’s Holi Hemp LLC subsidiary, documenting the disposition of certain equipment, inventory, and operating assets of a Vancouver, Washington facility and the associated preferential supply rights and contingent consideration.
Additional 8-K filings and the DEF 14A proxy statement provide information on corporate governance and capital structure. These documents cover stockholder approval to increase authorized common stock from 150,000,000 to 600,000,000 shares, amendments to the Articles of Incorporation to implement that increase, and the election of directors and ratification of the independent registered public accounting firm. Another 8-K reports a change in fiscal year-end from March 31 to December 31 and the plan to file a transition report on Form 10-K for the nine-month period from April 1, 2025, through December 31, 2025.
Through Stock Titan, users can access IGC Pharma’s 10-K, 10-Q, 8-K, and proxy materials as they appear on EDGAR, along with AI-powered summaries that highlight the main points of lengthy documents. These summaries help explain complex topics such as equity offerings under a shelf registration, asset sale terms, changes in authorized share capital, or fiscal year transitions. The filings page is also the place to monitor exhibits such as material contracts, legal opinions, and pro forma financial information referenced in 8-Ks.
For those tracking IGC Pharma’s stock, this page offers a way to review how the company reports on its clinical-stage operations, capital planning, governance decisions, and other material events through official SEC channels, with AI tools available to make dense regulatory text more accessible.
IGC Pharma completed the previously announced sale of certain equipment, inventory, and operating assets from its Holi Hemp LLC Vancouver, Washington facility. The transactions under the Sale of Assets and Manufacturing Agreement with Wellness Essentials Northwest LLC were consummated on November 13, 2025 for a fair value of approximately $2.7 million, following satisfaction of closing conditions.
The company filed unaudited pro forma condensed consolidated financial statements reflecting this disposition, including a balance sheet as of June 30, 2025 and a statement of operations for the three months ended June 30, 2025. The agreement is available as an exhibit, providing detailed terms of the asset sale and manufacturing arrangements.
IGC Pharma (IGC) reported a director’s stock option grant on a Form 4. The filing shows 750,000 options with a $0.35 exercise price tied to a transaction dated 10/17/2025. According to the footnote, the options vest equally over three years starting March 31, 2026, and expire on March 31, 2038. Following the grant, 750,000 derivative securities were beneficially owned, held directly.
IGC Pharma (IGC) reported an insider equity award. A director received 500,000 stock options on 10/17/2025 with an exercise price of $0.35 per share, according to a Form 4. The award reflects equity-based compensation and was recorded as directly owned derivative securities.
The options vest equally over three years starting on March 31, 2026, and carry an expiration date of March 31, 2038. Form 4s disclose changes in insiders’ beneficial ownership; option grants like this typically do not involve immediate cash transactions and do not represent an open-market purchase or sale.
IGC Pharma (IGC) reported an insider equity award. A director was granted 500,000 stock options at an exercise price of $0.35 per share on 10/17/2025.
The options vest equally over three years starting on March 31, 2026 and expire on March 31, 2038. The filing lists the holdings as direct ownership. This reflects routine equity-based compensation and does not involve an immediate cash transaction.
IGC Pharma (IGC) filed a Form 4 reporting insider equity activity on 10/17/2025. The reporting person, a Director and PFO, made a gift of 50,000 shares of common stock. Following the transaction, beneficial ownership of common shares was 1,134,252 (direct).
The filing also reports two option grants at an exercise price of $0.35: 1,000,000 options vesting equally over three years starting March 31, 2026 (expiration 03/31/2038), and 500,000 options that vest upon achievement of Board-set milestones (expiration 03/31/2036). These awards reflect equity compensation and do not involve cash transactions at grant.
IGC Pharma (IGC) reported insider activity on a Form 4. CEO and Director Ram Mukunda was granted stock options and made a share gift on 10/17/2025.
Grants include 3,000,000 options with a $0.35 exercise price, vesting equally over three years starting March 31, 2026, and 1,500,000 options with a $0.35 exercise price that vest upon Board‑set milestones. He also reported a gift of 100,000 shares of common stock. Following these transactions, he beneficially owned 3,992,678 shares, held directly.
IGC Pharma (IGC) reported results from its 2025 Annual Meeting held on October 10, 2025. Stockholders elected Ram Mukunda and James Moran as Class C directors to serve until the 2028 annual meeting and ratified Manohar Chowdhry & Associates as the independent auditor for the 2026 fiscal year.
Shareholders approved the grant of 5,000,000 shares of common stock to be issued from time to time to employees, advisors, directors, and consultants based on board- or CEO-set performance, vesting, and incentive metrics. They also approved an amendment to increase authorized common stock from 150,000,000 to 600,000,000 shares. A non-binding advisory vote set the frequency of say-on-pay votes at every three years.
Participation was strong, with 53,776,307 shares voted, representing approximately 59.22% of the 90,809,112 shares outstanding and entitled to vote. Broker non-votes totaled 18,341,638.
IGC Pharma, Inc. reported that its wholly owned subsidiary Holi Hemp LLC, doing business as HH Processors, entered into a Sale of Assets and Manufacturing Agreement with Wellness Essentials Northwest Inc. The Buyer will acquire equipment, inventory, and a ready-to-move facility and assume employee, utility, lease, and other operating obligations.
The parties agreed on a fair value of approximately
IGC Pharma, Inc. prospectus supplement describes securities the company may offer and highlights capital needs and risks tied to its drug and hemp-related businesses. The company has reserved millions of shares for incentive plans, restricted stock, and unit conversions and disclosed a September 2024 share purchase agreement for 588,235 shares at a total of $200,000. The document lists primary uses of proceeds, including working capital, funding pre-clinical and clinical trials for IGC-AD1 and TGR-63, AI development to streamline trials, lab and GMP facility development, marketing, patent filings and potential acquisitions. Key risk factors include funding sufficiency, regulatory approvals (including FDA INDA and Phase 2 trials), reliance on third parties for trials and manufacturing, intellectual property protection, market acceptance of phytocannabinoid/hemp-based products, geopolitical and economic conditions across multiple regions, and data security or IT disruptions.
IGC Pharma, Inc. proxy materials disclose details of the company’s equity plans, insider trading rules, and Audit Committee review for Fiscal 2025. Equity compensation plans approved by security holders show 13,823,529 shares available, representing 15.21% (figures presented in the filing). The filing cautions that future equity issuances could dilute market price, earnings per share, and book value per share if shares are issued below market or via low conversion prices. The company states it did not grant any stock options, SARs, or similar option-like instruments in Fiscal 2025. The Insider Trading Policy applies to directors, officers, employees and is filed as Exhibit 19.1. The Audit Committee reviewed audited financial statements with management, discussed required matters and auditor independence with Manohar Chowdhry & Associates, and recommended inclusion of the audited financial statements in the Annual Report for Fiscal 2025.